Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the results and potential impact from the phase 3 CEPHEUS trial.

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for ...

TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily ...

Joe DePinto, MBA, discusses the complexity of the cell and gene therapy ecosystem and the need for collaboration with ...

During a Case-Based Roundtable® event, Daniel J. George, MD and participants discussed combination regimens for intermediate ...

R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS ...

Susan L. Slager, PhD, discusses some of the recommendations for genetic testing in individuals with a family history of ...

The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...

The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no ...

Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...

In an interview, Vincent Law, of Moffitt Cancer Center, discussed a new study that offers hope for patients with melanoma ...

Slager, PhD, endowed professor of lymphoma research at Mayo Clinic, discusses the use of polygenic risk scoring to assess ...